In a Nutshell
MOTS-c is not FDA-approved, and no published randomized controlled trial in humans supports the fat-loss, energy or metabolic uses it is sold for.
MOTS-c is a mitochondrial-derived peptide — encoded by mitochondrial rather than nuclear DNA, which is unusual and is the source of most of the scientific interest in it. Research associates it with metabolic regulation, insulin sensitivity and exercise response.
It is marketed for fat loss, energy and metabolic health. There are no published randomized controlled trials in humans supporting those uses, and FDA states it has identified no human exposure data for compounded products containing it 1.
MOTS-c is not an FDA-approved drug. On July 23, 2026 an FDA advisory committee voted 7–5 (with two abstentions) to recommend it for the 503A Bulks List — for obesity and osteoporosis — contrary to the conclusions presented by FDA staff reviewers 2. FDA has not acted.
If fat loss is your goal, the treatments with substantial human evidence are the approved GLP-1 medications — see our GLP-1 hub.
What MOTS-c Is
Almost all of your DNA sits in the cell nucleus. Mitochondria — the structures that produce cellular energy — carry a small separate genome, and MOTS-c ("mitochondrial open reading frame of the twelve S rRNA type-c") is a short peptide encoded there.
The scientific interest is legitimate: peptides encoded by mitochondrial DNA that signal to the rest of the cell represent a real and relatively recently described biology. Research has associated MOTS-c with AMPK signaling — a central regulator of cellular energy — and with metabolic responses to exercise.
The gap between "this is interesting biology" and "injecting a synthetic version produces a benefit in humans" is where this page sits.
Current FDA and Compounding Status
MOTS-c is not approved by FDA for any use.
It appears on FDA's list of bulk substances "nominated but withdrawn" — previously in Category 2, until the nominator withdrew the nomination 1. Even so, FDA elected to continue evaluating the free-base and acetate forms on its own initiative — which is why the substance still came before the committee.
That is not FDA clearance: removal from Category 2 does not by itself make a substance eligible for compounding. Eligibility runs through one of three statutory routes under Section 503A — an applicable USP/NF monograph, being a component of an FDA-approved drug, or the 503A Bulks List — and every other 503A requirement still applies. For this substance FDA found no applicable USP/NF monograph and no FDA-approved drug containing it, so the 503A Bulks List is the only route identified in FDA's current review. The committee's vote did not add it to that list and changed no present authority to compound it.
FDA's stated concern: compounded MOTS-c "may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization," and FDA "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration" 1.
Full context on the July vote is on our FDA peptide status page.
What the Evidence Actually Shows
Evidence tier: C.
| Claim commonly made | What the evidence supports |
|---|---|
| Promotes fat loss | Animal and cell studies. No published human RCT. |
| Improves insulin sensitivity | Preclinical and observational association. No human RCT of administered MOTS-c. |
| Boosts cellular energy / endurance | Mechanistic plausibility via AMPK. No controlled human outcome data. |
| Slows aging | Not supported by human evidence. |
Small observational studies have associated circulating endogenous MOTS-c concentrations with insulin sensitivity, obesity and other metabolic measures, though direction and strength vary between populations. That is a meaningfully different claim from demonstrating that injecting synthetic MOTS-c changes outcomes — a distinction marketing material tends to elide.
Does MOTS-c Help With Weight Loss?
This is the most-searched question about MOTS-c, and it deserves a direct answer: there is no controlled human evidence that MOTS-c produces weight loss.
The contrast with the approved options is stark. GLP-1 medications have large randomized trials with published outcomes — semaglutide at roughly 15% mean body-weight reduction at 68 weeks, tirzepatide at roughly 21% at 72 weeks. Whatever MOTS-c may eventually prove to do, nothing comparable exists for it.
If fat loss is the goal, starting with the evidence-backed pathway is the rational move. See GLP-1 medications for weight loss and expected weight loss timeline.
Safety and What Is Unknown
- Human safety data: absent. FDA has identified no human exposure data via any route 1
- Long-term effects: unknown
- Immunogenicity and characterization: FDA's stated concerns about aggregation, peptide-related impurities and difficulty confirming what a preparation contains
- Interactions with diabetes medication: no human interaction study exists. Animal findings make additive glucose lowering a plausible concern, particularly with insulin or medicines that directly stimulate insulin release such as sulfonylureas — not with every diabetes medicine equally. Magnitude unknown. Do not stop or reduce prescribed medication; tell the clinician managing it
- Pregnancy and breastfeeding: no data; not appropriate
- Product risk: most MOTS-c in circulation is research-grade — see peptide sourcing and quality
Red Flags — Seek Care Now
- Symptoms of low blood sugar — shakiness, sweating, confusion, palpitations — particularly if you take insulin or a sulfonylurea
- Fever, spreading redness, swelling or pus at an injection site
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
- Chest pain or fainting
On Dosing
This page does not provide dosing protocols. No human dose-finding study has been completed, so no established dose exists. If you are using MOTS-c regardless, tell your clinician — particularly if you take any glucose-lowering medication.
What You Can Do About It
If low energy or stubborn metabolic markers brought you here, both are worth investigating properly. Fatigue commonly traces to thyroid function, testosterone and other hormones, iron studies, vitamin D, sleep quality or sleep apnea. Insulin resistance is measurable, and has treatments with real evidence behind them. Visceral fat specifically responds to interventions we can document — see muscle-loss prevention on GLP-1s and visceral fat in menopause.
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians, with programs built around labs, hormones and body composition and outcomes published in the peer-reviewed literature. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning. For metabolic concerns specifically, that assessment measures what is actually happening rather than inferring it from the scale. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Can you get MOTS-c on prescription?
MOTS-c is not an FDA-approved drug, and FDA has not acted on the July 2026 advisory recommendation.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- GLP-1 Medications for Weight Loss — the evidence-backed pathway for fat loss
- Are Peptides Legal in the US?
- How to Tell If a Peptide Is Legitimate
- Peptide Therapy: What It Is and Who It's For
Frequently Asked Questions
What does the MOTS-c peptide do?
MOTS-c is a peptide encoded by mitochondrial DNA, associated in research with AMPK signaling, metabolic regulation and exercise response. What administering synthetic MOTS-c does in humans has not been established in controlled trials.
Does MOTS-c help with weight loss?
There is no controlled human evidence that it produces weight loss. It was considered by the FDA advisory committee under proposed indications including obesity, but a proposed indication is not evidence of effect. Approved GLP-1 medications have large published trials; MOTS-c does not.
What are the negative side effects of MOTS-c?
Largely unknown, because human studies have not been done — FDA states it has identified no human exposure data. Theoretically, a peptide affecting insulin sensitivity could interact with glucose-lowering medication. Unregulated products carry separate contamination and dosing risks.
Is MOTS-c legal to buy?
It is not an FDA-approved drug. Products sold online are typically research-grade, labeled not for human use. An FDA advisory committee recommended it for compounding eligibility in July 2026, but FDA has not acted, and compounding eligibility is not the same as approval.
Is MOTS-c worth trying?
On current evidence there is no reliable basis for saying it works in humans for any marketed use. If the underlying goal is fat loss, energy or metabolic health, each has assessment pathways and, in several cases, treatments with substantially better evidence.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two controversial peptides," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html [Accessed: Jul. 25, 2026]. ↩
- The Hill, "FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists," Jul. 2026. [Online]. Available: https://thehill.com/homenews/5987510-fda-committee-votes-peptides/ [Accessed: Jul. 25, 2026]. ↩
- C. Lee, J. Zeng, B. G. Drew, T. Sallam, A. Martin-Montalvo, J. Wan, S. J. Kim, H. Mehta, A. L. Hevener, R. de Cabo, et al., "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance," Cell Metabolism, vol. 21, no. 3, pp. 443-54, Mar. 2015, [Online]. Available: https://doi.org/10.1016/j.cmet.2015.02.009. PMID: 25738459. [Accessed: Jul. 25, 2026]. ↩
- J. P. H. Wilding, R. L. Batterham, S. Calanna, M. Davies, L. F. Van Gaal, I. Lingvay, B. M. McGowan, J. Rosenstock, M. T. D. Tran, T. A. Wadden, et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," The New England Journal of Medicine, vol. 384, no. 11, pp. 989-1002, Mar. 2021, [Online]. Available: https://doi.org/10.1056/NEJMoa2032183. PMID: 33567185. [Accessed: Jul. 25, 2026]. ↩
- A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, S. Wharton, L. Connery, B. Alves, A. Kiyosue, S. Zhang, B. Liu, M. C. Bunck, et al., "Tirzepatide Once Weekly for the Treatment of Obesity," The New England Journal of Medicine, vol. 387, no. 3, pp. 205-216, Jul. 2022, [Online]. Available: https://doi.org/10.1056/NEJMoa2206038. PMID: 35658024. [Accessed: Jul. 25, 2026]. ↩